COX-2 expression is predictive for early relapse and aromatase inhibitor resistance in patients with ductal carcinoma in situ of the breast, and is a target for treatment
D Generali, FM Buffa, S Deb, M Cummings, LE Reid, M Taylor, D Andreis, G Allevi, G Ferrero, D Byrne, M Martinotti, A Bottini, AL Harris, SR Lakhani, SB Fox
British Journal of Cancer | NATURE PUBLISHING GROUP | Published : 2014
BACKGROUND: Stratification of patients for treatment of ductal carcinoma in situ (DCIS) is suboptimal, with high systemic overtreatment rates. METHODS: A training set of 95 tumours from women with pure DCIS were immunostained for proteins involved in cell survival, hypoxia, growth factor and hormone signalling. A generalised linear regression with regularisation and variable selection was applied to a multiple covariate Cox survival analysis with recurrence-free survival 10-fold cross-validation and leave-one-out iterative approach were used to build and test the model that was validated using an independent cohort of 58 patients with pure DCIS. The clinical role of a COX-2-targeting agent w..View full abstract
Awarded by Cancer Research UK
Awarded by National Institute for Health Research
This study was partly funded by the Victorian Breast Cancer Research Consortium, the NHMRC, the Cancer Council Victoria, the Cancer Council Queensland, the Victorian Cancer Biobank and Cancer Research UK and Oxford NHS Biomedical Research Centre. We also acknowledge the NIHR Oxford Biomedical Research Centre, UK, and Associazione Ricerca in Campo Oncologico Onlus, Cremona, Italy.